SNA

Exicure to Present at Upcoming Scientific Conferences

Retrieved on: 
Thursday, October 28, 2021
Biotechnology, Genetics, Health, Oncology, Spherical nucleic acid, Neurology, Inflammation, Technology, Architecture, SNA, CET, Patient, NASDAQ, FA, Mouse, Lists of diseases, ICM, Therapy, Pharmaceutical industry

Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics.

Key Points: 
  • Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics.
  • Exicure is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA).
  • Exicures therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors.
  • Exicure is based in Chicago, IL and in Cambridge, MA.

Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP

Retrieved on: 
Friday, October 15, 2021
Headache, Risk, Instagram, PRIME, Private Securities Litigation Reform Act, Solution, LinkedIn, Arthralgia, Social responsibility, Myalgia, Breakthrough therapy, European Medicines Agency, Chikungunya, SEC, Ageing, Marketing, Rash, NYSE, Disease, CHIKV, Patient, Public health, Life, Emergent, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Vaccine, Food, SNA, Fast Track, Review, Twitter, Safety, Fever, EBS, VLP, Emergent BioSolutions, Pharmaceutical industry

GAITHERSBURG, Md., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the companys investigational chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, in a single dose.

Key Points: 
  • GAITHERSBURG, Md., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the companys investigational chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, in a single dose.
  • CHIKV VLP is the only VLP-based vaccine currently in clinical development for active immunization against chikungunya disease.
  • Emergent has achieved a major milestone as we begin our phase 3 study for our single-dose chikungunya vaccine candidate, said Karen L. Smith, M.D., Ph.D., executive vice president and chief medical officer at Emergent BioSolutions.
  • Early this year, the company announced two-year persistence data from its Phase 2 safety and immunogenicity study of CHIKV VLP in 415 healthy adults.

Special Needs Alliance Announces 2021 - 2022 Board of Directors

Retrieved on: 
Monday, October 11, 2021
Program, SNA, SSI, Multimedia, Advance healthcare directive, Trust, Alliance, Personal, Wills, Awareness, Special needs trust, View, Intellectual disability

"This is particularly an inspiring year because it's the 20thanniversary of the Special Needs Alliance, and I couldn't be more excited to serve as SNA's president this year," said Special Needs Alliance President Mary O'Byrne.

Key Points: 
  • "This is particularly an inspiring year because it's the 20thanniversary of the Special Needs Alliance, and I couldn't be more excited to serve as SNA's president this year," said Special Needs Alliance President Mary O'Byrne.
  • The Special Needs Alliance has more than 150members in 45states.
  • Membership signifies that themember attorney is recognized amongst his/her peers as a notable attorney practicing special needs law.
  • The Special Needs Alliance (SNA) is a national organization comprised of attorneys who practice law and advocate for people living with special needs and disabilities, the elderly, and their families.

Snap-on Incorporated to Webcast 2021 Third Quarter Results Conference Call

Retrieved on: 
Thursday, October 7, 2021
Retail, Construction & Property, Aerospace, Manufacturing, Technology, Other Automotive, Other Retail, General Automotive, Other Manufacturing, Other Technology, Aftermarket, Specialty, Automotive, Software, Other Construction & Property, Engineering, SNA, NYSE, Solution, Agriculture, Income, Mining, Government, Natural Resources, Internet, Aviation, Webcast, S&P 500, Download, Hand, Online shopping

Snap-on Incorporated (NYSE: SNA) will release 2021 third quarter results prior to the market open on Thursday, October 21, 2021.

Key Points: 
  • Snap-on Incorporated (NYSE: SNA) will release 2021 third quarter results prior to the market open on Thursday, October 21, 2021.
  • A conference call to discuss the results will be held at 10:00 a.m.
  • The conference call audio and accompanying slides will be webcast live via the Internet.
  • To access the call, visit https://www.snapon.com/EN/Investors/Investor-Events and click on the link to the webcast.

Exicure to Present at Upcoming Scientific Conferences

Retrieved on: 
Thursday, October 7, 2021
Oncology, Health, Infectious Diseases, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, NASDAQ, FA, Spherical nucleic acid, SNA, Inflammation, Architecture, Lists of diseases, Neurology, Therapy, Patient, Technology, Pharmaceutical industry

Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics.

Key Points: 
  • Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics.
  • Exicure is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA).
  • Exicures therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors.
  • Exicure is based in Chicago, IL and in Cambridge, MA.

Exicure to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference

Retrieved on: 
Monday, October 4, 2021
Health, Infectious Diseases, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, FA, Inflammation, Therapy, Conference, NASDAQ, Webcast, Patient, Lists of diseases, Neurology, Technology, Architecture, Spherical nucleic acid, SNA, Pharmaceutical industry

Exicure , Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced a presentation at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021.

Key Points: 
  • Exicure , Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced a presentation at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021.
  • Replays of the webcast will be available on Exicures website for 30 days following the webcast.
  • Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology.
  • Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA).

Socionext Wins 2021 "Best of Sensors" Award from Questex Sensors Converge

Retrieved on: 
Thursday, September 30, 2021
SOC, ASIC, IPS, Solution, Conference, CMOS, Multimedia, YouTube, Twitter, IOT, San José, Facebook, SNA, Sensor, Instrumentation

SANTA CLARA, Calif., Sept. 30, 2021 /PRNewswire/ --The SC123x series RF CMOS Sensors from SocionextAmerica has wonthe 2021 "Best of Sensors" Award in the Embedded Category, madebyQuestex's Sensors Converge, organizers of the annual Sensors Expo and Conference.

Key Points: 
  • SANTA CLARA, Calif., Sept. 30, 2021 /PRNewswire/ --The SC123x series RF CMOS Sensors from SocionextAmerica has wonthe 2021 "Best of Sensors" Award in the Embedded Category, madebyQuestex's Sensors Converge, organizers of the annual Sensors Expo and Conference.
  • The awards are given to companies for their cutting-edge advancements and achievements propelling the sensors industry forward.
  • The smart SC123x radar sensors from Socionext incorporate multiple antennas integrated inside a single package and provide many benefits and capabilities not available with other kinds of sensors.
  • For more information about Socionext radar sensors, visit http://socionextus.com/radar
    Socionext America Inc. (SNA) is the US branch of Socionext Inc. headquartered in Santa Clara, California.

Safety NetAccess Selected for Tactical Partnership With Omni Hotels & Resorts

Retrieved on: 
Tuesday, September 28, 2021
Omni, Omni Hotels & Resorts, Safety, Partnership, Internet, Broadcom Inc., Hunger, Instagram, Health, Coffee, Television, PGA, LinkedIn, YouTube, PGA Tour Champions, House Building Finance Corporation cricket team, Twitter, CEO, Wi-Fi, SNAP, Meal, Information technology, Technology, Shared Hope International, University, SNA, Restaurant, Education, GLOBE, Tourism

DALLAS, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Safety NetAccess, Inc. ("SNA") is pleased to announce they have been selected for a tactical partnership by Omni Hotels & Resorts ("Omni") to provide support and management of high-speed internet networks.

Key Points: 
  • DALLAS, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Safety NetAccess, Inc. ("SNA") is pleased to announce they have been selected for a tactical partnership by Omni Hotels & Resorts ("Omni") to provide support and management of high-speed internet networks.
  • This new partnership will combine SNA's vast guest room experience, superior guest support network, and proprietary Select Network Access Portal (SNAP) across Omni Hotels & Resorts' entire portfolio.
  • "We are very excited about our decision to partner with Safety NetAccess for guest internet support services at all of our properties," said Kathleen Erickson, Vice President of Information Technology at Omni Hotels & Resorts.
  • Omni Hotels & Resorts creates genuine, authentic guest experiences at over 50 distinct luxury hotels and resorts in leading business and leisure destinations across North America.

Exicure to Present at the Benzinga Healthcare Small Cap Conference

Retrieved on: 
Thursday, September 23, 2021
Biotechnology, Pharmaceutical, General Health, Health, Infectious Diseases, Genetics, Clinical Trials, Other Health, FA, Inflammation, Therapy, Conference, NASDAQ, Patient, CEO, Lists of diseases, Neurology, Technology, Architecture, Spherical nucleic acid, SNA, Pharmaceutical industry

Exicure , Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced that CEO David Giljohann will present at the Benzinga Healthcare Small Cap Conference on Thursday, September 30, 2021, at 3:20 PM ET.

Key Points: 
  • Exicure , Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced that CEO David Giljohann will present at the Benzinga Healthcare Small Cap Conference on Thursday, September 30, 2021, at 3:20 PM ET.
  • Exicure management will be available for one-on-one meetings to be held throughout the conference.
  • Investors can register to receive a free spectator pass for the event here .
  • Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA).

Exicure to Participate in Upcoming Scientific Conferences

Retrieved on: 
Wednesday, September 15, 2021
Biotechnology, Genetics, Health, Oncology, Neurology, Spherical nucleic acid, Technology, Inflammation, Architecture, Patient, Therapy, NASDAQ, Lists of diseases, FA, SNA, Pharmaceutical industry, Video game

Exicure , Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced participation in the following scientific conferences during the month of September:

Key Points: 
  • Exicure , Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced participation in the following scientific conferences during the month of September:
    Posters will go live at the start of the conference and will be available to conference attendees.
  • Exicure will add the posters to its website after each conference.
  • Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology.
  • Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA).